ライフサイエンスコーパス: LSIL

1 respective of HPV status (Normal = 2/20,10%; LSIL = 11/52,21%; HSIL = 25/92,27%; ICC = 2/5,40%).

2 atinocytes, and keratinocytes derived from a LSIL.

3 While only few normal samples, ASC and LSIL lesions, revealed copy number increases of 3q, 63%

4 results indicate distinct risks for HPV and LSIL.

5 Incident development of HPV infection and LSIL, analyzed by various demographic, behavioral, and c

6 in HPV 16/18-positive women with ASC-US and LSIL, respectively, and was 5% in hrHPV-positive but HPV

7 n is very low or absent in normal cervix and LSILs, is readily detectable in HSILs, and is very stron

8 The multi-center ASCUS-LSIL Triage Study has shown that HPV DNA testing can be

9 at the time of enrollment into in the ASCUS-LSIL (Atypical Squamous Cells of Undetermined Significan

10 ubjects were 821 women enrolled in the ASCUS-LSIL Triage Study who tested positive for HPV-16 at entr

11 a nested case-control design from the ASCUS-LSIL Triage Study, we selected women with incident cervi

12 pecimens from 86 women enrolled in the ASCUS-LSIL Triage Study.

13 No associations were found between LSIL regression and HPV status at baseline, sexual behav

14 h HPV infection in our study did not develop LSIL within a median follow-up period of 60 months.

15 e of 60 months for those who never developed LSIL.

16 from baseline (defined as the time of first LSIL diagnosis) for the 187 women with LSIL was 61 month

17 in behavioral and biological risks exist for LSIL, suggesting that HPV alone is not sufficient for th

18 ariable model showed the following risks for LSIL: HPV infection for less than 1 year (RH, 7.40; 95%

19 er or HSILs and 0.58 (95% CI, 0.37-1.04) for LSILs, compared with control subjects and adjusted for s

20 % confidence interval [CI], 0.2-0.7) and for LSILs/HPV (OR, 0.6; 95% CI, 0.3-0.9).

21 1.8-37.2) and a 5.3-fold increased risk for LSILs/HPV (95% CI, 1.2-23.7).

22 -44% to 29%) against the detection of HSILs, LSILs, and ASCUS, respectively.

23 lagen I, but this effect was not observed in LSIL-derived keratinocytes.

24 Both prevalent and incident LSIL cases were included in the analysis, with regressio

25 low-grade squamous intra-epithelial lesion (LSIL) regression in young women, and to examine the fact

26 d low-grade squamous intraepithelial lesion (LSIL) triage study (ALTS), who were monitored semiannual

27 t low-grade squamous intraepithelial lesion (LSIL) were significantly associated with the development

28 a low-grade squamous intraepithelial lesion (LSIL; benchmark indication for colposcopy).

29 low-grade squamous intra-epithelial lesions (LSIL; n = 52), high-grade (HSIL; n = 92), invasive cervi

30 high-grade squamous intraepithelial lesions (LSIL or HSIL).

31 low-grade squamous intraepithelial lesions (LSIL) who were triaged with tests for hrHPV and HPV 16/1

32 low-grade squamous intraepithelial lesions (LSIL) who were triaged with tests for hrHPV and HPV 16/1

33 low-grade squamous intraepithelial lesions (LSIL), 21 with high-grade squamous intraepithelial lesio

34 low-grade squamous intraepithelial lesions (LSIL), high-grade SILs (HSIL), and invasive carcinomas.

35 low-grade squamous intraepithelial lesions (LSIL, n = 14), and high-grade squamous intraepithelial l

36 5) or low-grade squamous epithelial lesions (LSILs; n=275) or who were cytologically normal (control

37 Low-grade squamous intraepithelial lesions (LSILs) have been described as a benign cytological conse

38 low-grade squamous intraepithelial lesions (LSILs), and high-grade SILs (HSILs).

39 low-grade squamous intraepithelial lesions (LSILs); were positive for human papillomavirus (HPV) wit

40 t HPV testing could be helpful in monitoring LSIL.

41 tion is likely to underlie the appearance of LSIL or HSIL soon after infection.

42 7475 to $101343 is expected for each case of LSIL identified by PAPNET-assisted rescreening and not b

43 follow-up, there were 109 incident cases of LSIL during the follow-up interval, with a median follow

44 one is not sufficient for the development of LSIL.

45 t significant risk factor for development of LSIL.

46 observation by cytology in the management of LSIL in female adolescents.

47 as about 70% for women with either ASC-US or LSIL.

48 V 16/18-negative women with either ASC-US or LSIL.

49 ned risk for HSIL associated with persistent LSIL underscores the need to closely monitor HIV-infecte

50 d declined with increasing disease severity [LSIL] (20%), HSIL, (17%), and cancer patients (7%); X2 t

51 ing was diagnosed as having a low-grade SIL (LSIL) on follow-up.

52 actobacillus jensenii (P < 0.01) compared to LSIL.

53 Cigarette smoking was a risk specific to LSIL, supporting the role of tobacco in neoplastic devel

54 volving 8587 women with ASC-US and 5284 with LSIL were found.

55 volving 8587 women with ASC-US and 5284 with LSIL were found.

56 losely monitor HIV-infected adolescents with LSIL.

57 ological risks thought to be associated with LSIL are, in fact, risks for acquisition of HPV.

58 e high precancer risk (similar to those with LSIL), possibly warranting immediate colposcopy.

59 C-US and 76% (CI, 74% to 79%) for those with LSIL.

60 omen (referent), and HIV-infected women with LSIL had 9-fold (P < .0001) greater risk.

61 first LSIL diagnosis) for the 187 women with LSIL was 61 months (IQR 34-80).

62 In HIV-infected women with LSIL, CIN-3+ risk was 7% (95% CI, 3%-11%).